Randy Ban sold $4.7M of INSP
See Remarks at Inspire Medical Systems, Inc.. 25,584 shares at an average of $183.50, traded Feb 13, 2025, filed Feb 18, 2025.
Score components
- +15RoleOfficer
- +25Trade size$4.7M at market
- +20Share of holdings soldSold 78% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-014860, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 9, 2025 | FTax withholding Common Stock10b5-1 | -314 | $182.15 | $57k | 2,767 | Feb 18, 2025 |
| Feb 13, 2025 | AGrant or award Common Stock10b5-1 | +5,076 | $0.00 | $0 | 7,843 | Feb 18, 2025 |
| Feb 13, 2025 | MOption exercise Common Stock10b5-1 | +25,000 | $67.63 | $1.7M | 32,843 | Feb 18, 2025 |
| Feb 13, 2025 | SOpen-market sale Common Stock10b5-1 | -2,500 | $178.54 | $446k | 30,343 | Feb 18, 2025 |
| Feb 13, 2025 | SOpen-market sale Common Stock10b5-1 | -1,000 | $179.41 | $179k | 29,343 | Feb 18, 2025 |
| Feb 13, 2025 | SOpen-market sale Common Stock10b5-1 | -1,330 | $180.79 | $240k | 28,013 | Feb 18, 2025 |
| Feb 13, 2025 | SOpen-market sale Common Stock10b5-1 | -3,770 | $181.90 | $686k | 24,243 | Feb 18, 2025 |
| Feb 13, 2025 | SOpen-market sale Common Stock10b5-1 | -3,242 | $182.90 | $593k | 21,001 | Feb 18, 2025 |
| Feb 13, 2025 | SOpen-market sale Common Stock10b5-1 | -2,541 | $183.79 | $467k | 18,460 | Feb 18, 2025 |
| Feb 13, 2025 | SOpen-market sale Common Stock10b5-1 | -3,452 | $184.81 | $638k | 15,008 | Feb 18, 2025 |
| Feb 13, 2025 | SOpen-market sale Common Stock10b5-1 | -3,824 | $185.84 | $711k | 11,184 | Feb 18, 2025 |
| Feb 13, 2025 | SOpen-market sale Common Stock10b5-1 | -3,341 | $186.96 | $625k | 7,843 | Feb 18, 2025 |
| Feb 13, 2025 | SOpen-market sale Common Stock10b5-1 | -584 | $187.66 | $110k | 7,259 | Feb 18, 2025 |
| Feb 13, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 0 | Feb 18, 2025 |
Related signals
Other insiders at Inspire Medical Systems, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Inspire Medical Systems, Inc. | John Rondoni See Remarks | $11k 109 shares | -1% | |
| 6Weak | Inspire Medical Systems, Inc. | Shawn mcCormick director | $167k 1,200 shares | -5% | |
| 8Weak | Inspire Medical Systems, Inc. | Shawn mcCormick director | $255k 2,000 shares | -7% | |
| 24Weak | INSPbuy Inspire Medical Systems, Inc. | Myriam Curet director | $804 5 shares | +0% | |
| 30Weak | Inspire Medical Systems, Inc. | Myriam Curet director | $616 6 shares | -0% | |
| 52Moderate | INSPsell Inspire Medical Systems, Inc. | Richard Buchholz Chief Financial Officer | $1.0M 11,000 shares | -20% | |
| 41Moderate | Inspire Medical Systems, Inc. | John Rondoni See Remarks | $259k 1,734 shares | -11% | |
| 10Weak | Inspire Medical Systems, Inc. | Shawn mcCormick director | $58k 360 shares | -1% | |
| 34Weak | Inspire Medical Systems, Inc. | Randy Ban See Remarks | $733k 3,947 shares | -35% | |
| 24Weak | Inspire Medical Systems, Inc. | John Rondoni Chief Technology Officer | $424k 2,287 shares | -13% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.